Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Xtandi

Xtandi®, Enzalutamide, is indicated for:

  • the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC)
  • the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
  • the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, are our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics